Hematology News

Anthos Therapeutics announced that the phase 2 AZALEA-TIMI 71 study was stopped early due to an “overwhelming reduction” in bleeding in patients with atrial fibrillation at high risk for stroke taking abelacimab vs. rivaroxaban.

September is National Sickle Cell Awareness Month.

Patients who have been hospitalized with systemic lupus erythematous demonstrate an increased risk for multiple cancer subtypes, as well as an increased risk for 5-year mortality after cancer development, according to data.

Concizumab prophylaxis reduced bleeding rates among patients with hemophilia A or B with inhibitors, according to results of the phase 3A explorer7 study published in The New England Journal of Medicine.

The first three patients who received an investigational gene therapy for sickle cell disease experienced dramatic reductions in complications related to sickle cell disease, according to results of a first-in-human study.

Apellis announced a corporate reconstructing to drive growth of Syfovre and Empaveli, which will include cost-cutting initiatives expected to save the company up to $300 million through 2024, according to a press release.

The FDA approved luspatercept-aamt as first-line treatment for anemia among certain adults with myelodysplastic syndrome.

In the ONCO-DVT trial, patients with cancer and isolated distal deep vein thrombosis had fewer thrombotic events at 1 year with 12-month vs. 3-month edoxaban therapy, a finding that could change clinical guidance, according to a speaker.

Anxiety and depression are prevalent psychiatric comorbidities among individuals with hemophilia, according to study results.

Researchers at Children’s Hospital of Philadelphia and Perelman School of Medicine at University of Pennsylvania developed an in vivo proof-of-concept model for the delivery of gene editing tools to treat blood disorders.